Tenofovir Alafenamide Fumarate (TAF) Effect on Residual Intrathecal Immune Activation

Summary

Many HIV-infected individuals on effective antiretroviral therapy with suppressed HIV RNA levels in blood as well as in cerebrospinal fluid have signs of low-level intrathecal inflammation. Our aim is to study if changing the nucleoside backbone in an antiretroviral regimen can decrease the residual intrathecal immune activation.

Timeline

Start

2016-05-02

Primary completion

2018-07-15

Completion

2018-07-15

Drugs

Indications